Pharmacological Management of Portal Hypertension: A Review Article | ||||
| Zagazig University Medical Journal | ||||
| Article 16, Volume 30, Issue 9.1, December 2024, Page 4928-4935 PDF (350.5 K) | ||||
| Document Type: Review Articles | ||||
| DOI: 10.21608/zumj.2024.278742.3271 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Mennatullah Ismail Ibrahim ELnaggar  1; Sohair Hanem Samir El-Menshawy2; Fatma Atwa Aly Shehata1; Nevertyty Mohamed Mahmoud3
| ||||
| 1Clinical Pharmacology Department, Faculty of Medicine, Zagazig university | ||||
| 2Clinical Pharmacology Department, Faculty of Medicine, Zagazig University. 2 Pathology Department, Faculty of Medicine, Zagazig University | ||||
| 3Clinical pharmacology department, Faculty of Medicine, Zagazig University, Egypt | ||||
| Abstract | ||||
| Background: Portal Hypertension is considered an abnormal elevation of pressure in the veins that drain blood from the visceral organs (e.g., the spleen) to the liver. This occurs due to elevated resistance to blood flow in the portal circulation with the development of collateral circulation to carry portal blood. Reducing portal pressure and avoiding portal hypertension-related problems are the goals of the pharmacological management of portal hypertension. Portal blood flow and hepatic vascular resistance determine portal pressure. We aimed to present an insight into the pharmacological management of portal hypertension. Conclusion: The main goals of current medications in portal hypertension. are to either reduce the formation of collateral circulation, hyperdynamic circulation, vascular hyperplasia, renin-angiotensin-aldosterone system (RAAS) activation, or to inhibit angiogenesis and fibrosis in the liver to decrease intravascular resistance. Portal hypertension causes splanchnic and systemic arterial vasodilation, which in turn activates the neurohumoral (increase in sympathetic activity and activation of the RAAS) and vasoconstrictive systems; this leads to increased cardiac output, increased blood volume, and sodium and water retention. Activation of the RAAS raises portal pressure, according to multiple investigations in cirrhotic animals and people | ||||
| Keywords | ||||
| Pharmacology; Management; Portal Hypertension | ||||
|
Statistics Article View: 17,018 PDF Download: 86 |
||||
